Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GMC-252 in Healthy Subjects and Type 2 Diabetes
NCT02686281Phase 1Terminated
- Sponsor
- Genmedica Therapeutics
- Start
- Sep 2012
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GMC-252 in type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Genmedica Therapeutics. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 14 days. Started Sep 2012; status: terminated.
02
Drugs
GMC-252
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02686281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686281.